Plus Therapeutics, Inc. (PSTV) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St futures steady with focus on Mideast talks, US-China summit
- Oil holds near two-week lows while diesel cracks hit record peak
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
July 21, 2022 4:05 PM EDTCompleted enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for Leptomeningeal Metastases
On track to complete key manufacturing objectives for cGMP 186RNL to support ongoing and planned clinical trials in 2022 and beyond
Multiple planned data presentations for glioblastoma and leptomeningeal metastasis indications planned for the second half of 2022
Management to host conference call today at 5:00 p.m. ET
AUSTIN, Texas, July 21, 2022 (GLOBE NEWSWIRE) --... More
